Sinusitis News and Research

Latest Sinusitis News and Research

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.

21 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

7 Jun 2010

Seasonal allergies may cause mild sleep-disordered breathing in young children: Research

The prevalence of mild sleep-disordered breathing in young children may fluctuate seasonally, suggests a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Rising number of asthma deaths in Australia: Study

According to a study by the Australian Institute of Health and Welfare the number of people over 45 dying from asthma attacks has increased in the past five years. In 2006 402 people had died of asthma. 2005 had only 318 deaths related to asthma in comparison. 2006 saw a 40 percent hike from the preceding three years says the report.

19 May 2010

DanActive drink reduces rate of common sicknesses in daycare children, say researchers

The probiotic yogurt-like drink DanActive reduced the rate of common sicknesses such as ear infections, sinusitis, the flu and diarrhea in daycare children, say researchers who studied the drink in the largest known probiotic clinical trial to be conducted in the United States. An additional finding, however, showed no reduction in the number school days missed.

19 May 2010

Final data from Open-Label studies of Cinryze in patients with HAE now available

ViroPharma Incorporated today announced the availability of final data from Open-Label studies of Cinryze (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov.

18 May 2010

Conservative therapies need to be recommended over routine use of OTC cough/cold products in children

Despite their widespread use by parents and caregivers, over-the-counter (OTC) cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.

4 May 2010

Conservative therapies recommended over routine use of OTC cough/cold products in children

Despite their widespread use by parents and caregivers, over-the-counter cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.

3 May 2010

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

BUSM professor receives Individual Biomedical Research Award

Richard Goldstein, PhD, a professor of pediatrics, division of pediatric infectious diseases, at Boston University School of Medicine, has been awarded an Individual Biomedical Research Award by The Hartwell Foundation and will receive $300,000 over three years as a Hartwell Investigator for his project titled, "A Vaccine Against Streptococcus Pneumoniae Based on Bacterial Surface Proteins Phylogenically Certified as Highly Conserved."

23 Apr 2010

Medtronic named 2010 MDEA winner for excellence in medical device design

Medtronic announced today that the company was named a 2010 Medical Device Excellence Award winner for excellence in medical device design for its Hydrodebrider System, manufactured by the company's Ear Nose and Throat business unit.

9 Apr 2010

Adolescent inhalant misuse can lead to deadly consequences

Approximately 143,000 young people aged 12 to 17 used inhalants in the past year while dealing with a condition like pneumonia, bronchitis, asthma, or sinusitis, according to a new study sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA). The study determined that the rate of use was 4.4 percent among adolescents who had at least one of the aforementioned respiratory conditions, similar to the rate among adolescents overall (4.1 percent).

8 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

EMA accepts MAA filing of ViroPharma's Cinryze for HAE

ViroPharma Incorporated today announced that the European Medicines Agency (EMA) has accepted the filing of its Marketing Authorization Application for Cinryze for acute treatment and prophylaxis against hereditary angioedema, which was submitted through the centralized procedure in March 2010. ViroPharma is seeking European approval for both prevention and treatment of acute attacks of hereditary angioedema.

25 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Sinusitis News and Research

Latest Sinusitis News and Research

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis

Seasonal allergies may cause mild sleep-disordered breathing in young children: Research

Rising number of asthma deaths in Australia: Study

DanActive drink reduces rate of common sicknesses in daycare children, say researchers

Final data from Open-Label studies of Cinryze in patients with HAE now available

Conservative therapies need to be recommended over routine use of OTC cough/cold products in children

Conservative therapies recommended over routine use of OTC cough/cold products in children

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

BUSM professor receives Individual Biomedical Research Award

Medtronic named 2010 MDEA winner for excellence in medical device design

Adolescent inhalant misuse can lead to deadly consequences

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

EMA accepts MAA filing of ViroPharma's Cinryze for HAE

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Sinusitis News and Research

Latest Sinusitis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in